Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
2002 1
2004 1
2007 1
2008 1
2010 1
2011 3
2012 3
2014 3
2015 1
2016 1
2017 1
2018 1
2019 4
2020 8
2021 8
2022 4
2023 5
2024 6
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
Furfaro F, Alfarone L, Gilardi D, Correale C, Allocca M, Fiorino G, Argollo M, Zilli A, Zacharopoulou E, Loy L, Roda G, Danese S. Furfaro F, et al. Among authors: loy l. Curr Drug Targets. 2021;22(7):760-769. doi: 10.2174/1389450122999210120205607. Curr Drug Targets. 2021. PMID: 33475057 Review.
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Drug Development in Inflammatory Bowel Diseases: What Is Next?
Petronio L, Dal Buono A, Gabbiadini R, Migliorisi G, Privitera G, Ferraris M, Loy L, Bezzio C, Armuzzi A. Petronio L, et al. Among authors: loy l. Pharmaceuticals (Basel). 2025 Jan 30;18(2):190. doi: 10.3390/ph18020190. Pharmaceuticals (Basel). 2025. PMID: 40006003 Free PMC article. Review.
How comparative studies can inform treatment decisions for Crohn's disease.
Privitera G, Bezzio C, Dal Buono A, Gabbiadini R, Loy L, Brandaleone L, Marcozzi G, Migliorisi G, Armuzzi A. Privitera G, et al. Among authors: loy l. Expert Opin Biol Ther. 2024 Sep;24(9):955-972. doi: 10.1080/14712598.2024.2389985. Epub 2024 Aug 12. Expert Opin Biol Ther. 2024. PMID: 39132872 Review.
Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S. Fiorino G, et al. Among authors: loy l. Expert Opin Biol Ther. 2019 Oct;19(10):1023-1030. doi: 10.1080/14712598.2019.1564033. Epub 2019 Jan 8. Expert Opin Biol Ther. 2019. PMID: 30601098 Review.
64 results